# A Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients With Moderate to Severe Hidradenitis Suppurativa

> **NCT06603077** · PHASE2 · COMPLETED · sponsor: **Avalo Therapeutics, Inc.** · enrollment: 253 (actual)

## Conditions studied

- Hidradenitis Suppurativa

## Interventions

- **DRUG:** AVTX-009 Regimen 1
- **DRUG:** AVTX-009 Regimen 2
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06603077
- **Lead sponsor:** Avalo Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-09-16
- **Primary completion:** 2026-02-23
- **Final completion:** 2026-03-17
- **Target enrollment:** 253 (ACTUAL)
- **Last updated:** 2026-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06603077

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06603077, "A Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients With Moderate to Severe Hidradenitis Suppurativa". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06603077. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*